Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gavere – page 8

1 677 clinical trials in Gavere, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gavere at a glance
1 677
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 677 trials in Gavere

Open in trial search

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Prostate cancer

Recruiting

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Novartis Pharma AG

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gavere

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and deprescribing strategies for patients with chronic gastrointestinal conditions.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

This primary care-based trial evaluates different approaches to reducing long-term PPI use, including on-demand therapy and alternative treatments with alginate formulations, aiming to establish optimal deprescribing protocols.

02 Primary Care Innovation

Ground-breaking research exploring patient-centered approaches to medication reduction in primary care settings, with a focus on chronic medication management.

  • Medication Optimization
  • Patient-Centered Care
  • Evidence-Based Deprescribing

The study compares different therapeutic strategies to help patients safely reduce their dependence on long-term acid suppression medication.

03 Therapeutic Strategy Comparison

Comprehensive evaluation of three distinct approaches to medication deprescribing, focusing on long-term outcomes and patient safety.

  • Comparative Effectiveness Research
  • Alternative Treatment Methods
  • Safety Monitoring

This research aims to establish evidence-based guidelines for reducing unnecessary long-term medication use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.